

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Girda, Eugenia

eRA COMMONS USER NAME (credential, e.g., agency login): egirda

POSITION TITLE: Gynecologic Oncologist

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
New York University, New York, NY	BA	05/2006	Biology
State University of New York, Stony Brook School of Medicine, Stony Brook, NY	MD	05/2010	Medicine
Memorial Sloan-Kettering Cancer Center, New York, NY	Resident	05/2013	Surgery
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY	Resident	06/2014	OB/GYN
UC Davis Medical Center, Sacramento, CA	Fellow	06/2017	Gynecologic Oncology

A. Personal Statement

I am a gynecologic oncologist and principal investigator on multiple clinical trials at Rutgers-Cancer Institute of New Jersey (CINJ). I work closely with both clinical and translational teams to elucidate mechanisms of therapeutic resistance in gynecologic tumor biology. I am a co-chair of Big TEN Gynecologic Oncology Research Consortium, leading the development of investigator-initiated trials. I am also a member of the Rutgers Clinical Investigations and Precision Therapeutics research program, as well as a member of Phase I clinical trials team at the Cancer Institute. Clinically, I maintain busy surgical practice where I perform minimally invasive surgery such as advanced laparoscopy and robotic assisted surgery, as well as complex open surgeries. I treat patients with gynecologic malignancies with standard of care systemic therapy, targeted therapy, and offer variety of early phase and late phase clinical trials. I am a principal or co-principal investigator on several investigator initiated, industry sponsored, and NCI/CTEP studies. I have experience in developing new agents through Phase 1 clinical trials in solid tumors, including using targeted therapies, immunotherapies, and first in human compounds. I have successfully completed and published the first safety cohort of patients using CD44 modulator, SPL-108, in conjunction with paclitaxel in platinum-resistant ovarian cancer patients. I have experience utilizing a wide array of immunotherapy agents in Phase 1 clinical trials including inhibitors of PD-1 and PD-L1 and novel immunotherapeutics including OX-40 agonists, intratumoral immunotherapies, and antibody inhibitors of DLL3. I am currently developing investigator-initiated trial of MDM2/MDMX inhibitor to evaluate the efficacy of immune checkpoint therapy and p53 inhibition in extra-renal clear cell tumors based on emerging data of the genomic fingerprint of these cancers. I also have experience in bench to bedside translation, establishing a patient-derived organoid model (PDO) in endometrial cancer for drug sensitivity testing in endometrial cancer.

1. **Girda E**, Hou J, Nelson D, Finlayson M, de Meritens AB, Chekmareiva M, Leiser A, Song M, Stephenson R, Chan N, Tergas AI, Vattakalam R, Wright JD, Yu H, Martincuks A, Kohut A, Palmer J, Rodriguez-Rodriguez L. Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. *Int J Gynecol Cancer*. 2022 Jun 24; PubMed PMID: 35750354.
2. Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, **Girda E**, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB. A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). *Cancer Med*. 2022 Apr 8; PubMed PMID: 35396812.

3. Glassman D, Patel JM, Hathout L, Thomas S, **Girda E**. Benign metastasizing leiomyoma in retroperitoneal lymph nodes with concurrent early stage cervical cancer. *Gynecol Oncol Rep*. 2022 Apr;40:100975. PubMed Central PMCID: PMC9011033.
4. Shapira-Frommer R, Mileshekin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, **Girda E**, Lopez Martin JA, van Dongen MGJ, Italiano A, Xu L, Jin F, Norwood K, Ott PA. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. *Gynecol Oncol*. 2022 Mar 28; PubMed PMID: 35361487.

B. Positions, Scientific Appointments and Honors

Positions and Scientific Appointments

- 2020 - Present Co-director of Gynecologic Oncology Research Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
- 2020 - Present Co-chair, Big Ten Cancer Research Consortium Gynecologic Working Group
- 2017 - Present Gynecologic Oncologist, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
- 2017 - Present Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Honors

- 2022 Excellence in Teaching Award, Saint Peters University Hospital, Obstetrics and Gynecology Residency program
- 2020 - 2022 Young Scholar Investigator Award, GOG Foundation
- 2019 New Investigator Award, GOG Foundation
- 2018 Special Appreciation Award, In Recognition of Outstanding Contributions to the Education of the ObGyn Residents, Rutgers Robert Wood Johnson Medical School
- 2018 Excellence in Teaching Award, RWJ Obstetrics and Gynecology residency program
- 2016 Excellence in Clinical Research, Gynecologic Oncology Scholarship Award
- 2013 - 2014 Administrative Chief Resident, Montefiore Medical Center
- 2013 Best Poster Award, American College of Obstetricians and Gynecologists (ACOG), District II
- 2013 Resident Teaching Award, Montefiore Medical Center
- 2010 Award for Art in Medicine, Stony Brook University School of Medicine
- 2006 Founder's Day Award, New York University
- 2002 - 2006 Dean's Honor List, New York University
- 2002 - 2006 Presidential Scholar, New York University, School of Arts and Sciences

C. Contribution to Science

1. I am the primary investigator for several NCI/ET-CTN and NRG Oncology cooperative group trial, investigating targeted and immunotherapy combinations in advanced gynecologic malignancies. These include a phase III trial of Pembrolizumab with Paclitaxel and Carboplatin in recurrent or advanced endometrial cancer (NRG-GY018), a PK study of Carboplatin clearance (NRG-GY022), and a surgical trial of non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancers among BRCA1 carriers (NRG-CC008). I have an investigator-initiated basket trial of Pembrolizumab in patients with advanced solid tumors and genomic instability, which is a multicenter trial. As an active phase I investigator, I am also a primary investigator of several dose escalation and dose expansion trials evaluating agents targeting EGFR, EP4, PI3K, LAG3, either alone or in combination with immune checkpoint inhibitors, as well as studies exploring use of different bispecific monoclonal antibodies targeting various tissue antigens. I am a primary investigator of a clinical trial exploring first-in-human use of novel enhanced tumor infiltrating lymphocytes in endometrial, ovarian, and cervical cancers. I am also an active member within the Precision Medicine Initiative at Rutgers which attempts to identify relevant drivers of tumor biology in all cancers, focusing on gynecologic malignancies.
 - a. **Girda E**, Zsiros E, Nakayama J, Whelan S, Nandakumar S, Rogers S, Benson B, Basile FG, Lotze MT, Brown RJ, Wenham RM. 1. Abstract 371932: A phase 1 adoptive cell therapy using drug-enhanced,

- tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies. 2022 ASCO Annual Meeting; 2022 June; Chicago, IL.
- b. Haribhakti N, Elliott A, Walker P, Marks EI, El-Deiry WS, Kurzrock R, **Girda E**, Thaker PH, Korn WM, Liu SV, Dizon DS. Abstract 366662: Genomic analysis of clear cell carcinoma. 2022 ASCO Annual Meeting; 2022 June; Chicago, IL.
 - c. Lagos G, Groisberg R, Elliott A, Walker P, Dizon DS, von Mehren M, Abraham J, Leu K, DeNardo B, **Girda E**, Trent JC. Abstract 381198: Using pan-sarcoma multiomic analysis for identifying sarcoma subtypes with immunogenic potential. 2022 ASCO Annual Meeting; 2022 June; Chicago, IL.
 - d. Lheureux S, Alqaisi H, Cohn DE, Chern J, Duska LR, Jewell A, Corr B, Winer IS, **Girda E**, Crispens MA, Dhani NC, Grant RC, Uthayakumaran S, Lee C, Bowering V, Wong H, Wang L, Bedard PL, Moscow J, Oza AM. Abstract 377460: A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. 2020 ASCO Annual Meeting; 2022 June; Chicago, IL.
2. During my time at UC Davis Medical Center, I worked to develop a patient derived organoid model for drug sensitivity testing in endometrial cancer. The focus of this research was to establish endometrial cancer patient-derived organoids (PDO) and to develop treatment response assays using various hormonal drugs and targeted agents. Fifteen patient-derived organoid cultures from primary endometrial cancer specimen were characterized. This novel model in gynecologic cancers was then used to develop drug sensitivity assays. PDO cultures had similar morphological and immunohistochemical characteristics to their tumors of origin. We are in the process of performing basic genetic characterization to further demonstrate that the organoids recapitulate the genetic heterogeneity seen in vivo. If confirmed, this model could provide an efficient alternative to the PDX and cell culture models while preserving cancer heterogeneity and allow for individualized treatment decisions in the clinical setting. One of the most exciting findings of our study was the near complete inhibition of all PDO cultures by STAT3 agent BBI-608. This agent is currently being studied in Phase II/III clinical trials for gastrointestinal and solid tumors, and may represent an important novel therapeutic agent in patients with endometrial cancer.
- a. Chen H, Shepherd-Littlejohn A, **Girda E**, Polanco-Echeverry G, Sahasrabudhe R, Toal T, Carvajal-Carmona L, Leiserowitz G, Smith L. Drug efficacy testing of targeted therapies in endometrial cancer organoids is partially predicted by cancer gene mutation data (Correct). *Gynecologic Oncology*. 2019 Jul 1; 154(1):e12. issn: 0090-8258
 - b. **Girda E**, Huang EC, Leiserowitz GS, Smith LH. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. *Int J Gynecol Cancer*. 2017 Oct;27(8):1701-1707. PubMed Central PMCID: PMC5627540.
 - c. Russo RM, **Girda E**, Kennedy V, Humphries MD. Two lives, one REBOA: Hemorrhage control for urgent cesarean hysterectomy in a Jehovah's Witness with placenta percreta. *J Trauma Acute Care Surg*. 2017 Sep;83(3):551-553. PubMed PMID: 28557847.

Complete List of Published Work in My Bibliography:

https://www.ncbi.nlm.nih.gov/myncbi/1Dgoj6a_hWLA3u/bibliography/public/